Want to see ENGN full AI Analyst Report?
ENGN Stock Chart & Stats
$1.82
-$0.06(-3.30%)
At close: 4:00 PM EDT
$1.82
-$0.06(-3.30%)
Day’s Range― - ―
52-Week Range$1.40 - $12.25
Previous Close$1.74
Volume651.33K
Average Volume (3M)1.07M
Market Cap
$117.90M
Enterprise Value$281.71
Total Cash (Recent Filing)$258.46M
Total Debt (Recent Filing)$33.35M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Sep 16, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding66,989,460
10 Day Avg. Volume866,912
30 Day Avg. Volume1,069,605
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside64.84% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet / Cash RunwayA strong cash position plus historically low leverage (debt-to-equity ~0.12) gives enGene durable operating flexibility during late-stage development and regulatory review. This reduces near-term financing pressure and supports execution on pivotal readouts and potential BLA activities.
Lead Program ProgressDemonstrated clinical activity (54% any-time CR) and a planned BLA filing represent structural progress from R&D toward commercialization. Clear regulatory milestones (pivotal 12-month data, BLA timeline) provide a defined path that can materially change the company’s revenue profile if durability and approval align.
Governance And Commercial ExperienceBoard continuity with an experienced commercial and financing executive at the helm strengthens oversight during the transition from clinical-stage to potential commercialization. This increases the company’s ability to navigate FDA interactions, capital planning, and launch readiness over the coming 2–6 months.
Bears Say
Sustained Cash BurnPersistent, cash-based losses and deeply negative operating/free cash flow imply continued dependence on external funding if revenues do not materialize. This elevates dilution and refinancing risk, meaning capital markets and financing strategy will materially affect long-term shareholder value.
Operational Disruption From RestructuringA 50% workforce reduction and C-suite turnover create execution risk: fewer resources and leadership churn can delay trials, regulatory interactions, or commercial preparations. Even with cost savings, such disruptions can materially affect timelines and the ability to sustain development momentum.
Single-Asset Concentration & Durability QuestionsReliance on one lead program with mixed durability metrics increases binary outcome risk. If 12-month durability and recent lower responses fail to meet regulatory or commercial expectations, the company’s long-term revenue and growth prospects could be materially impaired.
enGene Holdings News
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $1.40 and its highest was $12.25 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $117.90M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Sep 16, 2026 which is in 45 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Jun 15, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.466 by $0.036.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.44.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 66,989,460 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.466. Following the earnings report the stock price went up 9.259%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
enGene Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (64.84% Upside)
$3.00 (64.84% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 41.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.33%
Trailing 12-Months
Company Description
enGene Holdings
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$3.00
▲(64.84% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
4.47%
Insiders
0.73% Mutual Funds
1.89% Other Institutional Investors
92.92% Public Companies and
Individual Investors